+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Phase 2
Age: 18Years +
All Genders
ID07341737

Evaluation of SL-28 Cell Therapy for Safety and Anti-Tumor Activity in Adults With Advanced Solid Tumors

Led by Second Life Therapeutics · Updated on 2026-09-15

60

Participants Needed

3

Research Sites

8 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying SL-28, an allogeneic, non-genetically modified cell-based therapy, for treating advanced solid tumors in patients who have not responded to previous chemotherapy or immunotherapies. This open-label, multi-center trial includes a Phase 1 dose escalation to identify safe and effective doses and Phase 2 expansion cohorts. The study targets adults with a range of advanced solid tumors, including head and neck, lung, gastrointestinal, genitourinary, gynecologic cancers, breast cancer, and melanoma. Participants receive SL-28 intravenously once daily, five days a week for 12 weeks. The trial starts with a low dose group monitored for 12 weeks, after which higher dose groups may be enrolled to determine the highest safe dose without severe side effects. The study evaluates SL-28 as a single-agent therapy with dose escalation across up to three cohorts. During the study, participants undergo safety monitoring including assessments of adverse events, vital signs, ECG changes, and dose-limiting toxicities over 12 weeks. Researchers also measure anti-tumor responses using RECIST criteria. Participants are evaluated for organ function and performance status. The total involvement includes treatment and observation periods to assess safety, pharmacokinetics, and preliminary efficacy of SL-28.

CONDITIONS

Brief Title

SL-28 for Advanced Solid Tumours

Research Team

G

George Tetz, MD, PhD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here